Prediction: UnitedHealth Group Stock Will Soar in 2026

Source The Motley Fool

Key Points

  • 2025 has been a year that UnitedHealth Group shareholders probably want to forget.

  • However, the health insurance giant should see brighter days ahead.

  • The issues plaguing UnitedHealth Group should only be temporary in nature.

  • 10 stocks we like better than UnitedHealth Group ›

It's inaccurate to call the largest health insurer in the country and the fourth-largest healthcare company by market cap an underdog. However, UnitedHealth Group (NYSE: UNH) looked more like an underdog in 2025 than it has in quite a while.

Shares of the healthcare giant are still down more than 30% year to date, after plunging as much as 53% at one point. Should investors avoid this beaten-down stock? Nope. I predict that UnitedHealth Group stock will soar in 2026.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »

A finger pointing to a drawing of a rocket with a stock chart and blue line sloping upward.

Image source: Getty Images.

A year to forget

Admittedly, 2025 is a year that most UnitedHealth Group shareholders will probably want to forget. The health insurance stock could have been a poster child for Murphy's Law: Nearly everything that could go wrong did go wrong.

UnitedHealth Group lowered its 2025 full-year earnings guidance in April. The company highlighted two primary culprits: higher-than-expected utilization in its Medicare Advantage plans and "unanticipated changes in the profile of Optum Health members impacting planned 2025 reimbursement."

The situation worsened less than a month later. UnitedHealth suspended its 2025 outlook altogether due to medical costs rising significantly more than anticipated. CEO Andrew Witty also unexpectedly left the company "for personal reasons."

To add insult to injury, The Wall Street Journal reported that UnitedHealth was the subject of a U.S. Department of Justice criminal investigation. Although the DOJ had not contacted the company at that point, the reports ultimately proved to be accurate.

Brighter days ahead

With all of this bad news, why do I think UnitedHealth Group stock will soar in 2026? I believe that the issues plaguing UnitedHealth are only temporary in nature.

Health insurers have an easy solution when medical costs exceed their projections: increase premiums. That's precisely what UnitedHealth is doing. Stephen Hemsley, who returned to run the company following Witty's exit last year after previously serving as CEO from 2006 to 2017, said in the third-quarter earnings call, "Repricing within UnitedHealthcare is on track to drive solid operating earnings growth from margin improvement within that business in 2026."

Granted, the challenges for Optum can't be addressed as quickly. Hemsley acknowledged this in the Q3 call, stating that initiatives to turn things around within the segment "will show more measured progress in 2026 and will take more time to fully bear fruit."

Still, I fully expect UnitedHealth will deliver solid earnings growth next year. As earnings go, so go share prices (eventually, anyway).

Investors are also forward-looking. They will look for UnitedHealth's earnings growth to further accelerate in 2027 and beyond. I think that's a reasonable assumption. Importantly, the company doesn't necessarily have to deliver this higher growth before the stock moves in anticipation of it.

What about the DOJ investigation? I doubt that it will be resolved by the end of next year. This process may take some time to complete. UnitedHealth Group has previously endured a civil investigation by the DOJ, which took a decade to conclude.

The good news, though, is that a Special Master appointed by the court in that case didn't find any evidence of wrongdoing by the company. Even if UnitedHealth doesn't have as positive an outcome with the current DOJ investigation, it could still emerge relatively unscathed.

Why my prediction might not happen

Making predictions is a risky business. There's always a chance you could be wrong. I'll readily admit that my prediction about UnitedHealth Group stock soaring next year may not come to pass.

If the stock doesn't enjoy strong momentum, I suspect it could be due to one reason. I'm confident that UnitedHealth's earnings will grow in 2026. However, the growth may not be sufficient to capture investors' attention if the current bull market continues to roar. In such an environment, UnitedHealth may not look as attractive compared to higher-growth stocks.

On the other hand, a market downturn could actually work to UnitedHealth's advantage. Investors could view the company's stability and improving bottom line more favorably. Whatever happens, I don't think anyone will see UnitedHealth Group as an underdog in 2026.

Should you invest $1,000 in UnitedHealth Group right now?

Before you buy stock in UnitedHealth Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $540,587!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,118,210!*

Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of December 1, 2025

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
After the Crypto Crash, Is an Altcoin Season Looming Post-Liquidation?The crypto market remains unsettled two months after the "October 10" liquidation wave, one of its largest ever. Bitcoin's price has erased all its year-to-date gains, quieting prediction
Author  TradingKey
Yesterday 10: 29
The crypto market remains unsettled two months after the "October 10" liquidation wave, one of its largest ever. Bitcoin's price has erased all its year-to-date gains, quieting prediction
placeholder
Bitcoin Pauses for Breath Above $92,000 as Bulls Weigh Next Run at $95,000Bitcoin consolidates above $92,000 and the 100-hour SMA as traders eye a breakout toward $96,450 or a potential retracement to $90,500 support.
Author  Mitrade
Yesterday 03: 12
Bitcoin consolidates above $92,000 and the 100-hour SMA as traders eye a breakout toward $96,450 or a potential retracement to $90,500 support.
placeholder
Gold Price Forecast: XAU/USD flat lines near $4,200 ahead of US PCE inflation releaseGold price (XAU/USD) trades on a flat note near $4,205 during the early Asian trading hours on Friday. Rising US Treasury yields and upbeat US jobs data cap upside for the precious metal. Traders might prefer to wait on the sidelines ahead of the key US inflation data.
Author  FXStreet
Yesterday 03: 10
Gold price (XAU/USD) trades on a flat note near $4,205 during the early Asian trading hours on Friday. Rising US Treasury yields and upbeat US jobs data cap upside for the precious metal. Traders might prefer to wait on the sidelines ahead of the key US inflation data.
placeholder
AUD/USD holds steady above 0.6600; remains close to two-month high ahead of US PCE dataThe AUD/USD pair enters a bullish consolidation phase during the Asian session on Friday and oscillates in a range around the 0.6600 round figure, just below a nearly two-month high, touched the previous day.
Author  FXStreet
Yesterday 01: 36
The AUD/USD pair enters a bullish consolidation phase during the Asian session on Friday and oscillates in a range around the 0.6600 round figure, just below a nearly two-month high, touched the previous day.
placeholder
The 2026 Fed Consensus Debate: Not Hassett, It’s About Whether Powell Stays or GoesKevin Hassett, White House National Economic Council Director, is poised to succeed Jerome Powell as the next Federal Reserve Chair. This development signals a potentially more dovish mon
Author  TradingKey
Dec 04, Thu
Kevin Hassett, White House National Economic Council Director, is poised to succeed Jerome Powell as the next Federal Reserve Chair. This development signals a potentially more dovish mon
goTop
quote